tiprankstipranks

ProSomnus announces updated trial data on FLOSAT

ProSomnus announced updated clinical trial data, presented at the ProSleep 2023 Users Conference earlier this month. The updated data indicate that the First Line Obstructive Sleep Apnea Treatment study, FLOSAT, is on track to achieve all endpoints. Key findings to date include: Precision oral appliance therapy is effective, and non-inferior to CPAP, as a first-line treatment for moderate to severe OSA; Precision OAT was effective among 90% of moderate and 85% of severe OSA patients; Precision oral appliance therapy was preferred by patients, with 98% continuing therapy at three months versus 22% discontinuing CPAP therapy over the same period of time; In an intention to treat analysis factoring efficacy and adherence, precision OAT demonstrated twice the mean disease alleviation as CPAP. “The updated data and analysis from FLOSAT is validation that precision oral appliance therapy with ProSomnus devices is an effective front-line treatment for moderate to severe OSA,” said Len Liptak, Co-Founder and Chief Executive Officer of ProSomnus. “This is an important finding. Each year millions of people worldwide are diagnosed with moderate to severe OSA. An estimated 40% of them refuse CPAP. Over two and a half million people have been impacted by the recent CPAP recall and seek alternatives. The results of this study indicate that precision OAT with ProSomnus devices is an effective, and preferred, option for these patients.”

Protect Your Portfolio Against Market Uncertainty

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on OSA:

Disclaimer & DisclosureReport an Issue